This episode reviews articles about asthma from the May/June 2019 issue of AllergyWatch:
- Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis.
- Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison.
- Indirect Treatment Comparisons and Biologics.
- Endotypes of severe allergic asthma patients who clinically benefit from anti‐IgE therapy.
- Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma.
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
- Dr. Lee was on an advisory board for Teva.
- Dr. Kuruvilla has received consulting fees from AstraZeneca.
- Dr. Fineman – Speaker: AstraZeneca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.
Episode 2
ACAAI presents this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to the procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that may be referenced.
